Shares of Elliman, other realtors fall after $1.78 billion broker commission verdict

By Chibuike Oguh and Jonathan Stempel NEW YORK (Reuters) -Shares of Douglas Elliman, Compass and eXp World Holdings closed lower on Wednesday after the companies were sued for allegedly conspiring to artificially inflate their commissions from home sales. The proposed class action was filed on Tuesday in Kansas City, Missouri, just hours after a jury…

Read More

GSK to pay $1 billion for exclusive license to J&J’s hepatitis B therapy

(Reuters) -GSK will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson’s hepatitis B therapy, the British drugmaker said on Tuesday. JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018. Exclusive rights to the therapy will fuel the expansion of GSK’s own…

Read More